Becton, Dickinson and Company (BD) has plans to set up a $200m (€165m) drug delivery device manufacturing facility in Zaragoza, Spain.
Construction works for the new facility are slated to commence later this year.
In the initial stage, the Zaragoza plant will employ 150 people and cover an area of 8,000m². BD anticipates having up to 600 employees in the plant that will cover 30,000m² by 2030.
To be developed as a completely digital site, the plant will achieve sustainability and eco-efficiency standards, the company noted.
BD pharmaceutical systems worldwide president Eric Borin said: “BD’s new plant in Zaragoza will produce drug delivery devices, primarily for pharmaceutical companies that supply the European market with drugs in pre-fillable syringes such as vaccines and other biologic drugs.
“This new plant will also add needed capacity to support major vaccination campaigns, such as the one currently taking place in response to the Covid-19 pandemic.”
In December last year, the company announced a $1.2bn investment over four years to boost manufacturing capacity and technology for pre-fillable and advanced drug delivery systems as part of its 2025 growth strategy.
The new Spain plant is part of this strategy and will be the company’s fourth in the country.
BD operates three production sites in Spain, in San Agustín de Guadalix, Fraga and Almaraz. These plants manufacture a total of ten billion medical devices a year and have 1,500 employees.
The facility in Fraga is a major site for producing Covid-19 vaccination injection devices.
BD Spain and Portugal general director Lourdes López said: “After the December 2020 announcement of BD’s intention to build a new plant in Europe, a detailed site location search process resulted in Zaragoza, Aragon being selected because of the optimal conditions offered by the region, the synergies that could be produced with BD’s Fraga facility, and the results and excellent performance of the plants that currently exist in Spain.”
Earlier this month, BD reported revenues of $4.9bn in the second fiscal quarter ended 31 March, representing an increase of 15.4% on a reported basis, compared with $4.25bn in the same period last year.